Aclarion, Inc. (ACONW)
ACONWNASDAQ-CMMedical Specialities
$0.0214
0.0000 (0.00%) today
Regular session, Nov 13, 3:59 PM ET
- Market cap
- $61.7k
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.0200 to $0.1990
- Average volume
- –
- Previous close
- $0.0214
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $18.0k | $21.0k | $25.0k | $34.0k |
| Gross profit | $2,000 | $4,000 | $8,000 | $15.0k |
| Operating income | -$1.99m | -$2.99m | -$2.90m | -$2.75m |
| Net income | -$1.89m | -$2.85m | -$2.75m | -$2.62m |
Last four quarters: revenue $98.0k, margin -10319.4%, free cash flow –
News
8 latest- Stock Indexes Finish Lower as Tech Stocks RetreatBarchart · 4 minutes ago
- Biotech Stocks On The Rise - AKAN +88%, CUE +49%, ADAG +24%, ANTX +23%, NRXP +10% RTTNews · 8 minutes ago
- Stocks Mixed as Nvidia Erases Overnight GainsBarchart · 13 minutes ago
- Disney’s Experiences Segment Hit Record Quarterly Revenue of $10.1 Billion as Cruise Days Surged. Can the Momentum Last?The Motley Fool · 23 minutes ago
- Gladstone Capital (GLAD) Q4 2026 Earnings Call TranscriptThe Motley Fool · 30 minutes ago
- Should You Buy Walmart Stock Before Nov. 19? History Has a Clear Answer.The Motley Fool · 32 minutes ago
- Golar LNG (GLNG) Q3 2026 Earnings Call TranscriptThe Motley Fool · 37 minutes ago
- Anthropic’s IPO is Tomorrow. Should You Buy ANT at a $1.4 Trillion Valuation?The Motley Fool · 38 minutes ago
The company
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy ('MRS'), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain.
- Sector
- Health Care
- Industry
- Medical Specialities
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- aclarion.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.